Home Most Popular Johnson & Johnson: Kenvue Spin-Off Unlikely To Drive Market-Beating Returns

Johnson & Johnson: Kenvue Spin-Off Unlikely To Drive Market-Beating Returns

0
Johnson & Johnson: Kenvue Spin-Off Unlikely To Drive Market-Beating Returns

Johnson & Johnson Vision offices in Silicon Valley

Funding Thesis

Johnson & Johnson (NYSE:JNJ) is a famend worldwide healthcare conglomerate celebrated for its intensive array of prescribed drugs, medical units, and client healthcare merchandise. In 2022, Johnson & Johnson was acknowledged as essentially the most useful model within the pharmaceutical sector, with a formidable

Fiscal 12 months

2024 2025 2026 2027 2028 2029 2030 2031
Income (b$) 89.5 94.0 98.7 103.6 108.3 112.6 117.1 121.2
Rev. Progress -11% 5.0% 5.0% 5.0% 4.5% 4.0% 4.0% 3.5%
EPS ($) 10.9 11.4 12.0 12.6 13.1 13.7 14.2 14.6
EPS Progress 8.4% 5.0% 5.0% 5.0% 4.5% 4.0%

4.0%

3.0%
Ahead PE 17 16 16 16 15 15 15 15
Inventory Value ($) 185 183 191 201 197 205 213 219